NEFL and myeloid sarcoma: Background and Aims: Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (GFAP) are emerging biomarkers of axonal damage and astrocytic activation, both likely paramount in MS associated neurodegeneration.